Podcasts about fractional cto

Episode #39 of "Can I get that software in blue?", a podcast by and for people engaged in technology sales. If you are in the technology presales, solution architecture, sales, support or professional services career paths then this show is for you! Today Chad and Steve are talking with Alex Jukes, formerly the CTO of Intropic and now a Fractional CTO helping startups navigate their journey from concept to shipping product. Alex gives a nice in-depth look at how he approaches the job of Fractional CTO, basing it on the tasks the company needs him to perform instead of just a part time bucket of hours.Our website: https://softwareinblue.com Twitter: https://twitter.com/softwareinblue LinkedIn: https://www.linkedin.com/showcase/softwareinblue Make sure to subscribe or follow us to get notified about our upcoming episodes: Youtube: https://www.youtube.com/channel/UC8qfPUKO_rPmtvuB4nV87rg Apple Podcasts: https://podcasts.apple.com/us/podcast/can-i-get-that-software-in-blue/id1561899125 Spotify: https://open.spotify.com/show/25r9ckggqIv6rGU8ca0WP2 Links mentioned in the episode: Why Salesforce Must Die: https://www.linkedin.com/feed/update/urn:li:activity:7284878009906417664/Nobody is Hiring Junior Engineers: https://www.linkedin.com/posts/alex-jukes_no-ones-hiring-juniors-engineering-managers-activity-7295756561128259584-hGtH

CTOx addresses the challenges faced by technology leaders wanting to transition into fractional roles. In this episode, Adam Torres and Lior Weinstein, Fractional CTO and Founder of CTOx, explore Lior's background and what inspired him to start CTOx. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

CTOx addresses the challenges faced by technology leaders wanting to transition into fractional roles. In this episode, Adam Torres and Lior Weinstein, Fractional CTO and Founder of CTOx, explore Lior's background and what inspired him to start CTOx. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

Best way to bridge gaps between Tecnical Teams and Executive Leadership. Tom Altman shares his insight as a Fractional CTO at Altus CXO, AI & Cybersecurity Advocate, excels in aligning technology with business strategy to drive growth, innovation, and strong system foundations. https://altuscxo.com https://www.linkedin.com/in/tomaltman

Send us a textIn the second part of this conversation on digital solutions in bioprocessing, David Brühlmann and Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, discuss real-world examples of labs revolutionizing their workflows through smart digitalization. From real-time data monitoring to intercontinental data sharing, Simon highlights the practical benefits and exciting future potential of digital technologies in bioprocessing.Missed Part 1? In the previous episode, Simon Wieninger from Eppendorf Group addressed data silos, cloud technology, and security in biotech. Catch up on that episode before diving into Part 2!Key highlights from the episode:Choosing the Right Tools: Simon emphasized the importance of selecting the right digital tools and technologies to focus on what brings the most value, particularly in the bioreactor space. Real-time data access, even from your mobile device while walking your dog, is now possible!Data Sharing Across Sites: Simon shared a fascinating case where a U.S.-based biotech company and their CDMO in Germany shared real-time data through the cloud, breaking down silos and enabling collaborative analysis. Imagine the possibilities for your company!Looking to the Future: We explored the exciting potential of integrating bioprocessing data with clinical outcomes, particularly in cell and gene therapy. This holistic approach can revolutionize patient care and therapy development.As Simon succinctly puts it, scientists should focus on what they do best - biology. The burden of managing digital technologies should not overshadow their primary research and development activities. With specialized tools and expert support, biotechnologists can achieve greater efficiency and innovation without getting bogged down by technological complexities.The conversation between Simon Wieninger and David Brühlmann illuminates the transformative potential of digital tools in bioprocessing. From real-time monitoring to data harmonization and cross-site collaboration, these technologies are paving the way for more efficient and innovative bioprocessing practices.By strategically adopting these tools, scientists can focus on groundbreaking research, ultimately accelerating the development and delivery of life-saving therapies.Connect with Simon Wieninger:LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182Eppendorf Group: https://www.eppendorf.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textDigital transformation is reshaping industries worldwide, and biotech is no exception. With the integration of cloud technologies, AI, and data harmonization, bioprocessing is becoming smarter, more efficient, and more innovative. Catching up with digital revolutions in other sectors, biotech now stands at the threshold of tremendous change.In this episode of the Smart Biotech Scientist Podcast, David Brühlmann sat down with Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, to discuss the digital revolution sweeping through bioprocessing labs. From bioreactors to data lakes, Simon sheds light on the urgent need for a data-driven approach in biotech and how digital transformation is set to reshape the industry.Here are the top three key takeaways:Breaking Down Silos: The importance of consolidating data in one place to facilitate better analysis and collaboration across departments.Leveraging Cloud Technology: Simon emphasized that the biotech industry is ready to embrace cloud technologies for enhanced data management.Data Security Concerns: Addressing the common misconception about cloud security, Simon reassured that robust measures are in place to protect bioprocess data, making it as secure as banking data.The move towards centralized data storage, the integration of AI, and strategic collaborations are critical steps in this journey. The industry is poised for transformation, and as Simon aptly put it, “step by step,” we can harness the full potential of these digital solutions. As biotech continues to evolve, the fusion of technology and biological science will undoubtedly lead to groundbreaking advancements, streamlining processes, and unlocking new possibilities in the field.Connect with Simon WieningerLinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182Eppendorf Group: https://www.eppendorf.comEnjoyed this episode? Don't miss these related discussions:Episode 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl, co-founder and CTO of DataHowEpisode 05: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov, the co-founder and COO of DataHowNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textIn the ever-evolving world of biotechnology, the integration of artificial intelligence (AI) and synthetic biology is driving unprecedented advancements. This transformative power was the focus of this podcast episode of the Smart Biotech Scientist, where host David Brühlmann engaged in a thought-provoking conversation with Haotian Guo, CEO and Founder of Ailurus on the role of AI in bioprocessing, the significance of wet lab validation, and the exciting future of programmable biology.The conversation with Haotian Guo sheds light on the profound impact AI is having on the field of biotechnology. AI's role as a "co-pilot" in scientific endeavors has enabled researchers to tackle complex problems with greater efficiency and accuracy. Haotian Guo shares: "AI helps us tremendously with tasks that are tedious and time-consuming for humans, such as reading and summarizing vast amounts of scientific literature. This capability allows scientists to focus on higher-order thinking and problem-solving."Key insights for this conversation:AI as Co-Pilot: Discover how Ailurus leverages AI to enhance research workflows. Haotian emphasizes using AI to read and analyze massive amounts of scientific literature, making it an invaluable co-pilot in the lab.Synthetic Biology Meets AI: Learn how synthetic biology combined with AI-driven models is opening new horizons for developing DNA designs and optimizing protein engineering. This fusion of biology and technology is proving to be a game-changer.Challenges in Biotech: Haotian candidly discusses the ongoing challenges, such as the need for wet lab validation and the high costs associated with data generation. Despite these hurdles, the potential for AI to streamline processes is immense.While the integration of AI and synthetic biology offers tremendous opportunities, Haotian Guo advises caution, particularly for those considering venturing into a biotech startup. He acknowledges the high-risk nature of startups, especially in an unpredictable economic landscape.However, he also underscores the importance of perseverance and preparedness, qualities crucial for navigating the biotech industry's challenges.In conclusion, Haotian Guo's insights paint a compelling picture of the future. The synergy between AI and biotech holds the promise of smarter, more efficient, and more accessible scientific research. By leveraging the strengths of both computational and experimental approaches, the biotech community is poised to achieve remarkable breakthroughs, transforming the landscape of healthcare and beyond.Connect with Haotian Guo:LinkedIn: www.linkedin.com/in/haotian-guoAilurus: www.ailurus.bioNext Steps:Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Casey Stanton kicks off Season 2 of the Fractional CMO Show with an exciting update on his journey since the last episode in 2023. From personal milestones like buying a historic home to professional advancements such as launching CTOx, Casey shares why now is the perfect time to embrace the role of a fractional CMO. Discover how AI is reshaping marketing departments, why leadership remains critical, and how fractional CMOs can secure high-paying, fulfilling roles while solving bigger problems. Get ready to learn, grow, and thrive in the evolving marketing landscape. Here's what we talked about:   Life! What I've been up to... My latest book "Find Your CMO" Launch of CTOx and the dynamic opportunities in fractional CTO roles Shrinking marketing departments and the rise of AI-driven tasks Why leadership and strategic vision will always require human oversight Predictions for the role of AI in the future of marketing Focusing on leadership and strategy rather than execution Building lasting client relationships and pricing services appropriately Avoiding the “agency trap” and maintaining high profit margins Subscribe to the podcast so you don't miss an episode!   If you'd like me to answer your question on an upcoming episode, share your question at: https://cmox.co/podcast

Send us a textBiotechnology is rapidly evolving as innovation addresses real-world needs. At the cutting edge of this evolution, synthetic biology and AI-driven protein design are revolutionizing our approach to complex processes like protein purification.In this episode of the Smart Biotech Scientist podcast, host David Brühlmann talks with Haotian Guo, CEO and Founder of Ailurus, about the modern advancements in synthetic organelles and their transformative impact on protein purification.Haotian Guo introduces a groundbreaking approach inspired by nature's processes. Instead of relying solely on chromatography, synthetic biology mimics how organelles in cells, like beta cells purifying insulin, naturally segregate and process proteins. This innovation simplifies and optimizes bioprocessing, offering a more efficient alternative to traditional techniques.Key takeaways from this conversation:Revolutionary Advances in Protein Purification: Haotian discusses the innovative use of synthetic membrane-less organelles to simplify and enhance protein purification processes, drawing inspiration from natural cellular mechanisms.Combining AI with Synthetic Biology: Learn how the integration of AI and biotechnology can accelerate advancements and create more efficient bioprocesses, unlocking potential for rapid development in biologics.Scalability and Practical Applications: Insight into how these new technologies are being scaled from lab environments to industrial applications, maintaining high purity and yield, and the potential roadblocks and solutions encountered along the way.Through innovation rooted in imitation of natural processes and amplified by the power of AI, the future of protein purification looks drastically simplified, more efficient, and scalable. Synthetic organelles represent a leap forward, challenging the age-old techniques that have long dominated the field.Companies like Ailurus are not just contributing new tools but reshaping the roadmap for bioprocess development. As we stand on the brink of these technological advancements, the collaborative synergy between synthetic biology and artificial intelligence is setting the stage for revolutionary impacts across the biotech landscape.This podcast episode is filled with eye-opening insights and practical takeaways for anyone in the biotech or pharmaceutical industries. Whether you're an academic, a seasoned industry professional, or simply curious about the field, you'll find valuable perspectives to explore.Connect with Haotian Guo:LinkedIn: www.linkedin.com/in/haotian-guoAilurus: www.ailurus.bioNext Steps:Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textIn the second part of our conversation with Andrea Gough, Senior Director for Advanced Instruments' Solentim Portfolio, we'll explore how AI and machine learning have, in recent years, begun to transform various aspects of biotechnology, including cell line development (CLD). Andrea shares insights into how these cutting-edge technologies are being applied to the early stages of clone selection.AI's capability to analyze images and classify clone viability is another breakthrough. Feeding thousands of images into AI systems allows for efficient and accurate decision-making, reducing the workload on scientists.Here are three key takeaways from our conversation:Leverage AI and Machine Learning: Integrate AI to streamline clone selection and optimize cell line development processes. AI can identify key phenotypic identifiers and predict the best clones, driving efficiency and productivity.Diversify Expression Systems: While CHO cells dominate the protein therapy space, exploring alternative systems like HEK cells, MSCs, IPSCs, and even insect cells can offer unique benefits and improve gene therapy productions.Maintain Comprehensive Documentation: Ensure rigorous tracking and documentation of all processes. From certificates of analysis to raw image data, having meticulous records will safeguard your development process and aid compliance with regulatory standards.Tune in to the full episode for more insights on overcoming challenges in cell line development and tips for setting up successful bioprocessing workflows!Connect with Andrea GoughLinkedIn: www.linkedin.com/in/andrea-gough-72915282Advanced Instruments: www.aicompanies.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textCell line development (CLD) is a cornerstone of biologics production. This intricate process involves establishing a cell line capable of consistently producing a desired product, such as a therapeutic protein. While advancing science has refined numerous aspects of CLD, bottlenecks still exist, perpetuating challenges for scientists and industry professionals.In this episode of the Smart Biotech Scientist Podcast, Andrea Gough, Senior Director for Advanced Instruments' Solentim Portfolio, shared her extensive insights into the critical bottlenecks and innovative breakthroughs in cell line development.Here are three key takeaways from this episode:Understanding the DNA Integration Complexity: Andrea discusses the pros and cons of random integration, highlighting how it can become a bottleneck. She emphasizes the importance of choosing the right methodology from the very beginning to avoid the "needle in a haystack" scenario when searching for a good clone.Modern Tools for Ensuring Clonality: Technologies like imaging devices and single-cell dispensers have revolutionized the process. Learn about the shift from traditional limiting dilution methods to more sophisticated and efficient tools that provide better evidence for regulatory approval.Innovative Approaches to Accelerate Development: Discover how semi-targeted integration methods like transposon technology can significantly shorten timelines and improve clone stability. Andrea also explores the use of bulk pools to generate initial products quickly for pre-clinical and initial clinical studies.Developing cell lines is a complex process, but with advanced tools and innovative approaches, challenges can become opportunities. As biotechnology progresses, the ability to stay informed and flexible will remain essential for success.Catch the full episode to gain deeper insights and practical advice for advancing your cell line development projects!Join us for the next episode featuring Andrea Gough, as we explore how AI and machine learning are being integrated into the early stages of clone selection. This groundbreaking approach is transforming key areas of biotechnology, including cell line development (CLD).Connect with Andrea Gough:LinkedIn: www.linkedin.com/in/andrea-gough-72915282Advanced Instruments: www.aicompanies.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textThe intersection of artificial intelligence and biology presents immense opportunities for transforming bioprocess development. As the biotech industry continues to evolve, data-driven innovations are critical to optimizing biologics manufacturing. High-quality datasets stand at the forefront of this transformation, empowering researchers to make informed predictions and advance therapeutic discoveries. As AI tools become more commoditized, the focus shifts toward generating robust and extensive datasets to maximize the potential of machine learning in biological applications.Miniaturization has emerged as a vital enabler in this data-driven approach. Miniaturized systems allow researchers to conduct thousands of tests in an area no larger than the palm of your hand. This drastic reduction in material and resource requirements makes high-throughput screening feasible, economical, and scalable.Traditional liquid handling robots can manage thousands of tests per day, but each test requires considerable amounts of material, usually leading to high costs. Conventional systems can cost anywhere from $10 to $100 to get a single genotype sequence from discovery to sequencing. Miniaturization can bring these costs down to mere pennies per data point, making it possible to scale the dataset size exponentially.Key takeaways from our discussion:The future of AI in biology relies heavily on large, well-annotated datasets. Without them, the full potential of AI remains untapped. High-quality data enables more accurate predictions of protein structures and functions.Success in bioprocess development often involves collaboration with partners across the value chain. By working together, companies can leverage their unique strengths and expertise to overcome barriers and innovate more efficiently.Advancements in miniaturization technology allow for high throughput screening at reduced costs. This shift makes it viable to generate large datasets, speeding up the pace of discovery and making AI-driven predictions more accessible.This episode is essential for anyone eager to explore the transformative fusion of AI and biotechnology. Jeremy Agresti highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI, revealing how these innovations are solving complex challenges, driving breakthroughs, and shaping the future of science and medicine.Connect with Jeremy Agresti:LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/Triplebar: www.triplebar.comNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Send us a textBioprocess development is transforming the biotech industry, driving innovations in life-changing therapies. Success hinges on simplifying complex mechanisms and adopting advanced technologies. By integrating high-throughput screening and artificial intelligence, we can streamline workflows, reduce trial-and-error, and speed up biologics development. Embracing cutting-edge tools empowers scientists to maximize biology's potential, delivering efficient and impactful biotech solutions.In this episode of The Smart Biotech Scientist Podcast, host David Brühlmann explores these transformative methodologies with Jeremy Agresti, CTO and founder of Triplebar.Jeremy highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI. With tools that enhance predictability, scalability, and efficiency, Triplebar is set to transform biotechnology. By reimagining traditional methods, improving inputs, and leveraging modern technology, companies like Triplebar are driving a new era in bioprocessing, offering innovative solutions to complex biological challenges.Key Takeaways:Jeremy challenges the traditional view of scale-up issues, emphasizing that many problems can be solved at a smaller scale with better engineered strains and cell lines.By creating tiny bioreactors of droplets, Triplebar is able to perform high throughput screening, testing millions of mutations quickly and efficiently, and providing robust solutions for complex biological functions.The integration of massive data sets with AI allows for improved enzyme and protein design, unlocking the potential to innovate even when foundational understanding is limited.Ready to dive deeper? Join the journey of transforming bioprocess development with smart insights and pioneering spirit. Catch up with Jeremy's full story via the latest episode of the Smart Biotech Scientist podcast.Connect with Jeremy Agresti:LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/Triplebar: www.triplebar.comNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Send us a textIs your bioprocess facility wasting precious time and resources on traditional weighing system calibrations? In this eye-opening episode, Anders Tvegaard, COO of Eilersen Electric, reveals how digital load cell innovation is revolutionizing bioprocess monitoring and validation.Discover why weighing systems aren't the commodity technology you might think they are, and how choosing the right solution can dramatically reduce deviations and maintenance costs. Anders shares groundbreaking insights about Eilersen's water-free calibration system, which has helped customers save over a million liters of water and 700 man-hours in tank calibration time.Key takeaways:Why a single weighing system deviation can cost facilities $10,000+ in quality management aloneHow new digital load cell technology enables continuous monitoring during mobile vessel transportThe game-changing advantages of water-free calibration for single-use systemsReady to transform your bioprocess monitoring strategy? Listen now to learn how modern weighing technology can protect your products and streamline your operations.Connect with Anders Tvegaard:LinkedIn: https://www.linkedin.com/in/anders-tvegaard-3305a1Eilerson: https://eilersen.comNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Send us a textWhat do furniture manufacturing and bioprocess weighing have in common? In this fascinating episode, Anders Tvegaard, COO of Eilersen Electric Digital Systems shares the remarkable story of how his company evolved from solving a furniture maker's wood humidity measurement problems to revolutionizing pharmaceutical manufacturing.Fifty years ago, a simple request to build a more robust scale for weighing wood in sofa production led to the development of groundbreaking contactless load cell technology.Key takeaways for bioprocess professionals:Discover how a furniture problem sparked innovation in bioprocess weighing technologyLearn why traditional strain gauge technology may be compromising your mobile vessel operationsUnderstand how contactless load cells eliminate costly calibration deviations and production stopsFrom humble beginnings in a Danish basement to transforming modern bioprocessing, this episode reveals how cross-industry innovation is reshaping pharmaceutical manufacturing. Whether you're managing mixing tanks, mobile vessels, or single-use systems, you'll gain valuable insights into improving your bioprocess reliability.Ready to discover how furniture-inspired technology is solving today's bioprocessing challenges? Tune in now.Connect with Anders Tvegaard:LinkedIn: https://www.linkedin.com/in/anders-tvegaard-3305a1Eilerson: https://eilersen.comNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Keywords:  tech entrepreneur, startup journey, leadership in tech, business processes, small business tools, automation, digital transformation, fractional CTO, customer experience, technology solutions Summary:  In this episode, Mitch Beinhacker interviews tech entrepreneur Ben Johnson, who shares his journey from a young paperboy to a successful entrepreneur in the tech industry. Ben discusses the challenges he faced in various startups, the importance of leadership and clear communication in tech, and how he helps small businesses navigate technology and automation. He emphasizes the need for businesses to modernize and adapt to changing environments, and the role of fractional CTO services in providing affordable tech solutions for small companies. The conversation also touches on the significance of effective business processes and the tools available for small business owners to enhance their operations. Takeaways Ben's entrepreneurial journey began with a paper route at 13. He built an online travel agency during the early days of the internet. Identifying businesses that are behind the times is key to his strategy. Automation and online systems can significantly improve business efficiency. Leadership clarity is crucial for tech teams to be productive. The 'cone of uncertainty' helps businesses plan effectively. Small companies often overlook the importance of leadership training. Technology should serve business goals, not complicate them. Custom solutions can enhance customer experience beyond off-the-shelf products. Fractional CTO services provide affordable tech expertise for small businesses. Titles Overcoming Fear in Technology Adoption How to Modernize Your Business Operations Sound Bites "I feel like my entrepreneurial journey goes back to my paper route." "We actually built an online travel agency." "I specifically look for businesses where the core business is very much behind the times." Chapters 00:00The Journey of a Tech Entrepreneur 11:58Navigating the Challenges of Tech Startups 20:49The Importance of Leadership in Tech 29:59Building Effective Business Processes 39:02Tools and Automation for Small Businesses 54:04Connecting with the Tech Community

Send us a textCan artificial intelligence revolutionize drug development and reduce the staggering 90% failure rate in clinical trials? In this insightful episode, Lars Brandén, Director of Biology at Kolibri, shares his vision for the future of personalized medicine.Drawing from his extensive experience bridging academia and industry, Lars explores how AI models could transform our understanding of human disease by simulating body-wide cell signaling. He reveals an innovative approach to drug delivery using receptor ligand combinations that could dramatically reduce side effects and improve treatment efficacy.Key takeaways:Learn why maintaining "youthful naivety" in biotech innovation can lead to breakthroughs others deemed impossibleDiscover how combining AI with deep biological understanding could reduce clinical trial failure rates from 90% to potentially 15%Understand why interdisciplinary collaboration between biologists, software engineers, and other experts is crucial for advancing personalized medicineReady to dive deeper into the future of biotech innovation? Listen now to unlock Lars Brandén's insights on scaling therapies, navigating cross-functional teams, and maintaining scientific creativity in the face of challenges.Connect with Lars Brandén:LinkedIn: https://www.linkedin.com/in/larsbrandenNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textIn this episode, we explore the delicate dance between artificial intelligence and biological research with Lars Brandén, Director of Biology at Kolibri. From his early fascination with gene therapy to pioneering high-throughput screening centers at prestigious institutions, Lars shares invaluable insights on bridging the gap between academic innovation and industrial application.What sets this conversation apart is Lars' compelling perspective on why the popular "agile development" model doesn't always translate smoothly to bioprocess development – and why that matters for the future of drug development. His journey from the Karolinska Institute to leading cutting-edge biological research offers a unique lens on the evolution of biotech.Key takeaways for listeners:Learn why scientists must develop broader cross-disciplinary knowledge to effectively leverage AI tools in researchDiscover how AI could dramatically reduce drug development timelines and costs within the next five yearsUnderstand the potential for AI to democratize access to cell and gene therapies through optimized production methodsJoin us for this fascinating exploration of how domain expertise and artificial intelligence can work in harmony to accelerate breakthrough therapies. Whether you're a biotech professional or simply curious about the future of medicine, this episode offers valuable insights into the transformation of drug development in the AI era.Listen now to discover how the intersection of human expertise and artificial intelligence is reshaping the future of personalized medicine.Connect with Lars Brandén:LinkedIn: https://www.linkedin.com/in/larsbrandenNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Welcome to another insightful episode of the Pain Points Podcast! In this episode, we sit down with Bill Boulden, a seasoned technology leader and serial startip CTO for multiple innovative companies. Bill brings over 15 years of experience navigating the complex landscape of B2B technology, product design, and artificial intelligence. As a visionary in technology management, Bill has successfully led teams through the intricate process of product development and technology deployment across various industries. His ability to identify and overcome Pain Points has been instrumental in his journey from a Junior Developer to a Chief Technology Officer, and now as a Fractional CTO for forward-thinking companies like Favordrop and Edgeli, Inc. Whether you're a tech enthusiast, a business leader, or someone navigating the challenges of growth and innovation, this episode offers invaluable insights into turning Pain Points into powerful solutions.

Send us a textIn this insightful episode, Technical Development Leader at Flagship Pioneering Oliver Kraemer reveals why developing Advanced Therapy Medicinal Products (ATMPs) require a fundamental shift in thinking from traditional biologics development.Drawing from his extensive experience across Boehringer Ingelheim, Sanofi, and BMS, Kraemer challenges conventional wisdom about process development timing and demonstrates why early integration of process considerations is crucial for ATMP success.You will learn:Rethink Development Timing: Learn why incorporating process development earlier in ATMP programs dramatically reduces failure rates and prevents costly repetitionMaster Complexity: Understand the unique challenges of cell therapy development, including biological fitness and the critical interplay between cell lines, media, and processesNavigate Cost Implications: Discover strategies for managing the unexpectedly high development costs of ATMPs and making informed early decisions that impact commercial successReady to transform your approach to ATMP development? Join us for this must-listen episode as we demystify the path from bench to bedside in cell and gene therapy.Connect with Oliver Kraemer:LinkedIn: https://www.linkedin.com/in/oliver-kraemerNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop cell and gene therapies better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Send us a textIn this eye-opening episode, we explore the intricate landscape of Advanced Therapy Medicinal Products (ATMPs) with Oliver Kraemer, a technical development leader at Flagship Pioneering.Drawing from his extensive experience at industry giants like BMS, Sanofi, and Boehringer Ingelheim, Oliver challenges conventional wisdom about automation in cell and gene therapy while illuminating the crucial differences between biologics and ATMPs.Key Takeaways for Biotech Scientists:Discover why automation isn't the ultimate solution for advancing CGT development right now, and what this means for your process development strategyLearn how ATMP development requires a fundamental rethinking of the traditional research-to-development pipelineUnderstand the critical early-stage decisions in cell therapy development that can make or break your project timelineJoin us as Oliver shares invaluable insights from his journey from traditional biologics to cutting-edge cell therapies, including both iPSC-derived and donor-derived approaches. Whether you're a bioprocess developer, cell therapy researcher, or biotech professional, this episode offers practical wisdom for navigating the complex landscape of ATMP development.Ready to transform your understanding of cell therapy development? Listen now to gain insights that could save you months or even years in your development timeline.Connect with Oliver Kraemer:LinkedIn: https://www.linkedin.com/in/oliver-kraemerNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop cell and gene therapies better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Send us a textWant to peek behind the curtain of a leading Contract Development and Manufacturing Organization (CDMO)? In this inspiring episode, KBI Biopharma's Chief Scientific Officer Sigma Mostafa reveals the intricate world of bioprocess development and manufacturing.Sigma shares game-changing insights into accelerating biologics development without compromising quality. She also unveils how KBI is leveraging AI and machine learning to revolutionize everything from protein sequence analysis to formulation development.Key Takeaways:Learn how to master the art of seamless tech transferDiscover how to slash development timelines using innovative cell line technology and parallel processingLearn how AI and machine learning are transforming CDMO operations, from predicting developability challenges to automating lab processesReady to transform your bioprocess development journey? Tune in to hear Sigma's vision for the future of CDMOs and get actionable insights for your next project.Connect with Sigma Mostafa:Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817KBI: https://www.kbibiopharma.comNext Steps:Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a textIn this insightful episode, we're joined by Sigma Mostafa, Chief Scientific Officer at KBI Biopharma, who shares crucial insights on selecting the right CDMO partner for biotech development.Sigma brings a unique blend of scientific rigor and practical experience to the discussion, having worked on both sides of the CDMO relationship.Key Takeaways:Why harvest steps deserve more attention in bioprocess developmentThe truth about one-stop-shop CDMOs versus specialized partnersCritical factors in cell line and media selection that impact long-term successSigma emphasizes that successful CDMO partnerships hinge on transparent communication and cultural alignment, not just technical capabilities. She reveals that while one-stop shops seem convenient, partnering with specialized CDMOs who excel in specific areas often yields better results - as long as there's strong project coordination.Whether you're a startup navigating your first CDMO relationship or an established biotech company looking to optimize your partnerships, this episode provides actionable insights for making informed decisions that will impact your project's success for years to come.Listen now to transform your approach to CDMO selection and avoid costly pitfalls in your bioprocess development journey.Connect with Sigma Mostafa:Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817KBI: https://www.kbibiopharma.comNext Steps:Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a textStruggling to unravel the complexities of your bioprocess? Prepare for a paradigm shift as we dive into the world of Process Analytical Technology (PAT) with Katharina Dahlmann who is Application and PAT Expert at Hamilton.This eye-opening episode dissects how PAT is redefining biologics manufacturing, balancing its immense potential against real-world implementation hurdles. Katharina navigates us through the intricate journey of scaling up, from micro-bioreactors to large-scale bioreactors, unveiling the hidden gems of early PAT adoption. Whether you're a startup scientist or a seasoned biotech veteran, this episode is packed with insights to elevate your bioprocessing game.Tune in to uncover:Strategies for overcoming PAT implementation challengesExpert tips on scaling up your processes with confidenceA fresh perspective on cross-disciplinary collaboration in biotechDon't let bioprocess complexity hold you back – listen now and harness the power of PAT to decode your processes like never before!Connect with Katharina Dahlmann:LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180Hamilton: https://www.hamiltoncompany.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textUnlock the hidden potential of your bioprocess! In this eye-opening episode, David Brühlmann sits down with Katharina Dahlmann, Application and PAT Expert at Hamilton, to explore the game-changing world of Process Analytical Technology (PAT).Discover how PAT is revolutionizing biotech by providing unprecedented insights into cell behavior and process dynamics. Katharina challenges conventional wisdom, revealing that what we think we know about our processes may just be the tip of the iceberg. Learn how combining multiple PAT signals can extract meaningful knowledge, leading to more reproducible and efficient processes.You will gain valuable insights on:Leveraging PAT to optimize feeding strategies and reduce process timeBalancing inline and offline measurements for comprehensive process understandingThe future of PAT, including self-evaluating sensors and data modelingReady to take your bioprocessing game to the next level? Tune in now and transform your approach to bioprocess monitoring and control!Connect with Katharina Dahlmann:LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180Hamilton: https://www.hamiltoncompany.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textImagine predicting your bioprocess outcomes as easily as checking the weather forecast. Sound impossible? Not anymore. In this insightful episode, we dive deep into the world of digital twins and process models with Fabian Feidl, co-founder and CTO of DataHow.Discover how these cutting-edge tools are reshaping the biotech landscape, from simplifying complex processes to enabling personalized medicine. Fabian shares invaluable insights on implementing data-driven approaches, even for smaller companies with limited resources.Key takeaways:Learn how to start small and build powerful process models that drive real resultsDiscover the game-changing potential of combining AI with bioprocess expertiseExplore the future of personalized medicine through advanced data analyticsReady to revolutionize your biotech workflow? Tune in now and unlock the secrets to smarter, more efficient bioprocessing!Connect with Fabian Feidl:LinkedIn: https://www.linkedin.com/in/fabian-feidl-a52b36b3DataHow: https://datahow.chNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textAre you ready to decode the future of bioprocessing? In this eye-opening episode, we dive deep into the world of digital bioprocess development with Fabian Feidl, co-founder and CTO of DataHow.Discover how cutting-edge process models are transforming the biotech industry, bridging the gap between raw data and actionable insights.Key takeaways:Learn how process models can streamline development, reduce costs, and accelerate time-to-market for groundbreaking therapies.Explore the game-changing potential of personalized medicine through predictive modeling in CAR T-cell therapy.Uncover strategies to overcome organizational and technological barriers in adopting digital technologies for bioprocessing.From optimizing experimental design to enabling data-driven decision-making, this episode is packed with invaluable insights for biotech scientists and leaders. Tune in now to unlock the future of bioprocessing and take your research to the next level!Connect with Fabian Feidl:LinkedIn: https://www.linkedin.com/in/fabian-feidl-a52b36b3DataHow: https://datahow.chNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textAre you ready to dive into the cutting-edge world of biomanufacturing? In this episode, strategic consultant James Ryall unveils the staggering potential of bio-based products to revolutionize industries. From cultured meat to human breast milk, discover how cells are becoming the ultimate manufacturing facilities.James shares invaluable insights on scaling challenges, regulatory hurdles, and the critical importance of early preparation for biotech startups. Learn why biomanufacturing is poised to transform up to 60% of consumer goods and how to stay ahead in this rapidly evolving field.Gain expert strategies to:Navigate scaling and regulatory challenges with confidenceCreate bio-based products that outperform traditional alternativesTap into the immense opportunities in non-clinical biomanufacturingWhether you're a seasoned bioprocessing expert or a curious entrepreneur, this episode will ignite your passion for the biotech revolution. Tune in now and discover how to ride the wave of biomanufacturing innovation!Connect with James Ryall:LinkedIn: https://www.linkedin.com/in/james-ryallWebsite: https://www.jamesryall.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textIn this captivating episode, host David Brühlmann welcomes James Ryall, a strategic consultant with over two decades of experience in cell biology and regenerative medicine. From his groundbreaking work in skeletal muscle research to revolutionizing cultured meat production, James shares his fascinating journey through academia and industry.Discover how he's now helping biotech startups align their technical strategies with commercial outcomes, accelerating their path to market.You will gain invaluable insights on:Navigating the transition from academia to industryScaling cell production from lab quantities to industrial volumesIdentifying and pivoting to the right target market for biotech innovationsDon't miss this eye-opening discussion on simplifying bioprocessing and bringing game-changing products to life. Tune in now to supercharge your biotech career!Connect with James Ryall:LinkedIn: https://www.linkedin.com/in/james-ryallWebsite: https://www.jamesryall.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Leadership Tips for Tech Startup Founders: A Masterclass in Adaptability and Resilience Join Kyle Miller, a seasoned tech leader with over 25 years of experience and the founder of Backup Parachute Software, as he shares invaluable insights on navigating the challenges of leading a tech startup. With a proven track record of delivering successful projects for Fortune 100/500 companies, hedge funds, SMBs, and government agencies, Kyle offers practical advice on: • Streamlining operations: Focus on delivering what customers truly need. • Building a strong team: Align your team and keep them on track. • Navigating technical challenges: Leverage Kyle's expertise as a Fractional CTO. • Scaling your business: Learn from Kyle's experience as a SaaS operator. • Prioritizing customer needs: Create products that solve real-world problems. Whether you're a startup founder or a seasoned leader, this video provides actionable tips to help you overcome challenges and achieve your goals. Ready to unlock the true potential of your leadership? Schedule a free, one-on-one consultation today and discover how process-driven strategies can transform your organization. https://www.elitehighperformance.com/... Timestamps 0:00 - Introduction 5:23 - Thriving in Chaos and Crisis Leadership 7:15 – How do consistency and iteration drive success? 9:29 - What mindset shifts are essential for startups to avoid common scaling pitfalls? 11:53 - How can leaders embrace AI to enhance creativity and adaptability? 18:13 - How can leaders foster critical thinking and problem-solving in their teams? 19:19 -How does empowering employees boost motivation and success? 21:50 - How do constraints and ownership foster creativity, motivation, and high performance in a team? 26:38 - What is the purpose of Backup Parachute, and what types of services or platforms does it offer? 27:38 - What legacy does Kyle hope to leave behind? Kyle Miller Bio: https://kylemiller.com/bio/ Kyle's Company: https://backupparachute.com Find Susan Hobson, Founder & CEO of Elite High Performance, Top Leadership Coach & Author, at the following links: • https://www.elitehighperformance.com/... •   / jumpstartliving   •   / susanlhobson     / susanlhobson   Find Rob Kalwarowsky, World-Renowned Leadership Coach & TEDx Speaker, at the following links: https://www.elitehighperformance.com/... https://www.howtodealboss.com/howtode...   / robert-kalwarowsky     / bosscoachrobk     / bosscoachrobk  

Send us a textAre you ready to revolutionize your bioprocess development? Join David Brühlmann as he interviews Belma Alispahic, Chief Scientific Officer and Co-Founder of AnalysisMode, who unveils the game-changing potential of AI in biopharma.Discover how AI is transforming the industry, from drug discovery to manufacturing, and learn why it's no longer optional but essential for success.Key takeaways:Leverage AI to streamline experiments, reduce costs, and accelerate your path to marketGain insights into emerging AI technologies reshaping biopharma's futureLearn practical steps to integrate AI into your workflow, even with limited resourcesDon't miss this opportunity to stay ahead of the curve and unlock the full potential of your biotech projects. Tune in now to empower your scientific journey and simplify complex bioprocessing challenges with AI-driven solutions.Connect with Belma Alispahic:LinkedIn: https://www.linkedin.com/in/balispahicAnalysis Mode: https://analysismode.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

In this episode, Bob'nJoyce interview Corey Spitzer - serial entrepreneur, IT expert, start-up guru, and business change agent. Corey is a fractional CTO who helps clients solve the thorniest of product development and business growth challenges. He describes himself as an interpreter of sorts helping tech and business development people communicate and collaborate better. Corey brings a wealth of experience and stories to help start-up execs get the most from their IT development teams. He is passionate about making a difference in the organizations and people he serves. We all know someone who loves riding on bumpy roads and solving hairy dilemmas. Corey is one of those people. And no, despite describing his work like making sausage, he has never actually done it as best we know. Come on in. Grab a snack. Welcome!

Send us a textIs AI the secret weapon biotech scientists have been waiting for? In this eye-opening episode, we dive deep into the world of AI-driven bioprocess development with Belma Alispahic, Chief Scientific Officer and Co-Founder of AnalysisMode. Discover how AI is transforming the biotech landscape, from reducing downtime by 50% to unlocking unprecedented levels of precision in process optimization.Key takeaways:Learn how AI can slash experiment time by up to 80%, saving you valuable resourcesUncover the power of digital twins in fine-tuning your bioprocesses with unparalleled accuracyGain insights on overcoming data challenges to harness AI's full potential in your labDon't miss this game-changing discussion that could revolutionize your approach to bioprocess development. Tune in now and stay ahead of the curve in the rapidly evolving world of biotech!Connect with Belma Alispahic:LinkedIn: https://www.linkedin.com/in/balispahicAnalysis Mode: https://analysismode.comNext Steps:Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textIn this electrifying episode, we dive deep into the future of biotech with biotech influencer Benjamin McLeod. From quantum AI mapping cellular interactions to the game-changing potential of process analytical technology, Ben, who is also a Cell & Gene Therapy Segment Lead at NanoMosaic, unveils how artificial intelligence is set to transform the cell and gene therapy landscape.Discover why LinkedIn is becoming the new frontier for biotech networking and career advancement. Learn how combining AI with PAT could slash production costs and boost yields in ways you've never imagined.You will gain invaluable insights on:Leveraging AI to optimize bioprocesses and reduce costsThe evolving landscape of viral and non-viral gene therapiesStrategies for breaking into the cell and gene therapy fieldDon't miss this opportunity to stay ahead of the curve in biotech innovation. Tune in now and revolutionize your approach to bioprocessing!Connect with Benjamin McLeod:LinkedIn: https://www.linkedin.com/in/benjamin-mcleodNanoMosaic: https://www.nanomosaicllc.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textDiscover how a failed optometry dream led Benjamin McLeod to become a leading voice in cell and gene therapy. In this eye-opening episode, Ben, who is a Cell & Gene Therapy Segment Lead at NanoMosaic, shares his unconventional path from lab work to LinkedIn stardom, revealing how he bridges the gap between R&D and marketing in biotech.Learn how Ben's weekly science memes evolved into valuable content that attracts both lab techs and CEOs alike.Key takeaways:Gain insider tips on communicating complex science effectivelyLearn how to leverage social media to build industry credibilityDiscover the power of continuous learning in fast-paced biotech fieldsWhether you're a seasoned scientist or biotech enthusiast, this episode offers invaluable insights into the art of scientific communication. Tune in now to transform your approach to biotech development and communicating science.Connect with Benjamin McLeod:LinkedIn: https://www.linkedin.com/in/benjamin-mcleodNanoMosaic: https://www.nanomosaicllc.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textDive into the cutting-edge world of gene therapy as we unravel the complexities of AAV production. In this insightful episode, Ahmed Youssef, a seasoned AAV expert and Senior Process Development Manager at Ascend, explains how you can navigate the complex world of AAV scale-up and learn why thinking outside the box is crucial for success.Key takeaways:Leverage early expert advice to ensure your therapeutic's long-term viabilityExplore innovative technologies like doggy bone DNA to reduce impuritiesGain insights from industry pioneers to revolutionize your AAV production processFrom plasmid alternatives to cutting-edge CDMO strategies, this episode is packed with game-changing information. Don't miss out on these invaluable scale-up secrets that could transform your gene therapy projects.Tune in now and take your AAV production skills to the next level!Connect with Ahmed Youssef:LinkedIn: https://www.linkedin.com/in/ahmed-samir-youssefAscend: https://www.ascend-adv.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textUnlock the mysteries of AAV manufacturing in this eye-opening episode! Ahmed, a seasoned AAV expert and Senior Process Development Manager at Ascend, reveals insider strategies for biotech scientists navigating the complex world of gene therapy production.Discover why quality is the cornerstone of successful AAV development and how to avoid costly missteps in the journey from lab to clinic.Key takeaways:Learn to design a robust AAV manufacturing process that stands up to regulatory scrutinyMaster the art of balancing yield and quality for economically viable productionGain insights into cutting-edge analytical tools that ensure your AAV's efficacyFrom cell line selection to plasmid optimization, Ahmed breaks down the critical factors that can make or break your AAV project. Whether you're a biotech novice or a seasoned pro, this episode is packed with actionable advice to elevate your gene therapy game.Ready to revolutionize your approach to AAV production? Tune in now!Connect with Ahmed Youssef:LinkedIn: https://www.linkedin.com/in/ahmed-samir-youssefAscend: https://www.ascend-adv.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a textUnlock the secret weapon of biotech success! In this eye-opening episode, host David Brühlmann reveals how fractional CTOs are revolutionizing drug development, inspired by Michael Jordan's approach to greatness. Learn how this innovative strategy can slash timelines, mitigate risks, and give your biotech company a competitive edge.Discover the game-changing benefits of fractional expertise:Gain rapid access to broad biotech knowledge, navigating complex challenges with ease.Slash costs while tapping into C-level strategic guidance for critical growth phases.Accelerate business development through valuable industry connections and insights.Ready to transform your biotech journey? Tune in to explore how harnessing fractional expertise could be the catalyst your company needs.Don't miss this opportunity to level up your drug development game – listen now and stay ahead in the fast-paced world of biotech innovation!Next Steps:Schedule your free call at https://bruehlmann-consulting.com/assessment to discover how you can develop biologics better, faster, at a fraction of the cost with our Fractional CTO services.

Send us a textUnlock the secrets of successful bioprocess development with host David Brühlmann as he shares hard-won lessons from his 15+ years of experience leading technology transfers and technology innovation projects.Discover why prioritizing process development is crucial for transforming groundbreaking science into life-changing therapies. In this eye-opening episode, you'll learn:How to avoid costly mistakes in technology transfer and scale-up, saving you time and resourcesStrategies for balancing investor expectations with regulatory hurdles, keeping your project on trackTips for building a robust risk management strategy that impresses investors and navigates challengesFrom selecting the right cell lines to mastering the delicate dance of speed and quality, David unveils the hidden pitfalls that can derail even the most promising biotech innovations.Whether you're a seasoned scientist or a curious entrepreneur, this episode is packed with actionable insights to supercharge your bioprocess development. Don't miss out – tune in now and take your biotech game to the next level!Next Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a textWhat if your biomanufacturing facility could run itself, optimize its own processes, and operate non-stop? This isn't science fiction – it's the cutting-edge reality Professor Massimo Morbidelli is helping to create.In this captivating episode, the bioprocessing pioneer unveils how AI, continuous manufacturing, and revolutionary machine learning techniques are transforming the industry landscape.As a Professor Emeritus at ETH Zurich and Politecnico di Milano, and a co-founder of ChromaCon (now YMC) and DataHow, Massimo Morbidelli has been at the forefront of bioprocess innovation. He is currently the recipient of the ERC Advanced Grant Continuous Digitalisation of Bioprocesses (CoDiBio) at the Aristotle University of Thessaloniki.Discover how transfer learning is revolutionizing process development across molecules and scales, dramatically reducing time-to-market for new biologics. Learn why the integration of computer science and biology is crucial for staying competitive in the rapidly evolving biopharma landscape.You will gain invaluable insights onSlashing development costs,Maximizing productivity through 24/7 operationsLeveraging interdisciplinary knowledge to solve complex bioprocessing challengesAll are essential skills for thriving in the next era of biomanufacturing.Tune in now and revolutionize your approach to biopharma innovation!Connect with Massimo Morbidelli:Email: massimo “dot” morbidelli “at” polimi “dot” itNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

When set up properly, your technology should be shaped to your real estate team's way of doing things. It should support your vision and your dreams. It should enhance and improve your SOPs.But often we get things turned around and allow our tech to dictate how we operate. Instead of adding efficiency and profitability, our tech can add unnecessary cost and frustration.For advice on turning this around and to kick off Techtember, we bring you this incredibly helpful conversation with Justin Benson, Founder and CEO of Bara Agency and of Shilo.ai.Before starting Bara, a fraction Chief Technology Officer agency, he helped build Gluch Group, helped expand it to three states, sold hundreds of homes himself, and created their tech stack.Justin shares the three pieces of tech every team needs, ways to think about your tech budget, the most important question to ask when evaluating new and existing tech, and much more!Listen to this Techtember episode with Justin Benson to learn:- Why great salespeople are the bedrock of your team- His path from med school to tech startups to real estate agent and team leader operating in 3 states to fractional Chief Technology Officer- Where many ops leaders get stuck or reach their limit with technology- The most important question to ask as you're evaluating your tech- How to plan your tech budget- The three key elements of every tech stack, no matter your size- Avoiding the danger of changing too much tech too quickly- Specific ways to increase agent adoption of new tech- The promise of AI while it's still in its infancy- How to find the right person to lead your tech initiatives- Places he goes to keep up on tech trends and announcementsAt the end, learn about the enduring value of underdogs, chartering a jet, struggling to relax, and predicting the future based on the past.Connect with Justin Benson:- https://baraagency.com- https://shilo.ai- https://www.instagram.com/justinbensonConnect with Real Estate Team OS: - https://www.realestateteamos.com/subscribe- https://linktr.ee/realestateteamos- https://www.instagram.com/realestateteamos/

Send us a textImagine a world where biologic drugs are produced faster, cheaper, and with unprecedented precision.In this episode, we dive into that future with Professor Massimo Morbidelli, a trailblazer in bioprocessing innovation. As a Professor Emeritus at ETH Zurich and Politecnico di Milano, and a co-founder of ChromaCon (now YMC) and DataHow, Massimo Morbidelli has been at the forefront of bioprocess innovation. He is currently the recipient of the ERC Advanced Grant Continuous Digitalisation of Bioprocesses (CoDiBio) at the Aristotle University of Thessaloniki.From his groundbreaking work in continuous chromatography to spearheading AI-driven manufacturing, Morbidelli's 25-year journey has reshaped the biotech landscape.Discover how initial industry skepticism transformed into widespread adoption of continuous processing and machine learning. Prof. Morbidelli shares insights on his current project: a fully automated, end-to-end manufacturing process for plasmid DNA production.You will gain invaluable insights into:The evolution of continuous bioprocessing and its impact on productivity and yieldHow digitalization and machine learning are optimizing process development and manufacturingThe potential of transfer learning to dramatically reduce time-to-market for new biologicsDon't miss this opportunity to learn from a true visionary in the field.Tune in now to unlock the secrets of next-generation biomanufacturing and stay ahead of the curve in this rapidly evolving industry.Connect with Massimo Morbidelli:Email: massimo “dot” morbidelli “at” polimi “dot” itNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Send us a textAre your shake flasks holding back your bioprocess development? Discover how to transform them into smart bioreactors! In this game-changing episode, we talk with Jens Bayer about the groundbreaking DOTS platform. He is a deep tech entrepreneur and seasoned commercial leader, currently serving as Chief Commercial Officer at Scientific Bioprocessing.Jens reveals how this cutting-edge technology is bridging the gap between simple shake flasks and complex bioreactors, offering scientists unprecedented control and data insights.Learn how to:Generate real-time growth curves and monitor key parameters without invasive samplingRun fed-batch experiments in shake flasks, mimicking bioreactor conditionsOptimize your processes for better scalability and reproducibilityWhether you're a startup scientist or working in Big Pharma, this episode will revolutionize your approach to early-stage bioprocessing. Don't miss Jens' invaluable tips for designing successful shake flask experiments and his inspiring journey as a biotech entrepreneur.Ready to supercharge your bioprocess development? Tune in now and unlock the hidden potential of your shake flasks!Connect with Jens Bayer:LinkedIn: https://www.linkedin.com/in/jens-bayer-65a46350Scientific Bioprocessing: https://www.scientificbio.comNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a Text Message.Are shake flasks outdated relics or untapped goldmines of bioprocess development? In this eye-opening episode, we dive deep with Jens Bayer, a deep tech entrepreneur and seasoned commercial leader, currently serving as Chief Commercial Officer at Scientific Bioprocessing.Jens shatters common misconceptions about shake flasks, revealing why they remain indispensable tools in both industry and research settings.Discover:Why shake flasks are irreplaceable for rapid, cost-effective experimentationHow to overcome the "black box" challenge and extract crucial dataStrategies to optimize shake flask processes for better scalabilityFrom startups to Big Pharma, learn how mastering shake flask techniques can accelerate your bioprocess development and save precious resources. Whether you're a seasoned biotech pro or just starting out, this episode will transform how you approach early-stage bioprocessing.Ready to revolutionize your lab work? Tune in now and unlock the hidden potential of shake flasks!Connect with Jens Bayer:LinkedIn: https://www.linkedin.com/in/jens-bayer-65a46350Scientific Bioprocessing: https://www.scientificbio.comNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

In this episode, I was lucky enough to interview Tomé Duarte, the Fractional CTO and Founder of Penguin Objective.Tomé shares how he started the year strong with a record-setting Q1, crediting his meticulous use of spreadsheets for managing his operations and cash flow. Originally from Portugal, Tomé explains that he lived in Brazil and Ireland before settling back in his homeland, though his primary market is North America due to the fast-paced business culture. He emphasizes how the U.S. and Canadian markets align with his preference for growth-oriented and fast-moving business environments, contrasting this with the more traditional approaches often seen in Europe.Tomé discusses the origins of Penguin Objective, a company name derived from a government-issued list in Portugal, which resonated with him due to his connection to Linux. He explains that Penguin Objective focuses on providing fractional CTO services to pre-seed and early-stage startups, helping them navigate tech strategy, operations, and development challenges. He also delves into his entrepreneurial background, inspired by his father's civil engineering business and built on experience from previous ventures. Tomé talks about refining his ideal customer profile (ICP) and offering over time, shifting from large enterprises to startups that better align with his values and goals, while also sharing the importance of being adaptable and open to opportunities that may arise unexpectedly, much like his symbolic encounter with a frog mascot at a Web Summit event.Let's explore the vibrant streets of Porto and uncover Tomé Duarte's journey of resilience, innovation, and creative leadership on The First Customer!Guest Info:Penguin Objectivehttps://iamto.me/Tomé Duarte's LinkedInhttps://www.linkedin.com/in/tomeduarte/Connect with Jay on LinkedInhttps://www.linkedin.com/in/jayaigner/The First Customer Youtube Channelhttps://www.youtube.com/@thefirstcustomerpodcastThe First Customer podcast websitehttps://www.firstcustomerpodcast.comFollow The First Customer on LinkedInhttp://www.linkedin.com/company/the-first-customer-podcast/

Send us a Text Message.Dive into the cutting-edge world of autologous cell-based therapy with Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich. In this eye-opening episode, discover how MUVON Therapeutics' innovative approach to muscle regeneration is revolutionizing treatments for stress urinary incontinence and beyond.Learn how her team is tackling the challenges of bringing personalized medicine to market at scale, from navigating complex regulations to automating production processes.Listeners will gain invaluable insights on:Strategies for engaging with regulatory bodies to advance novel therapiesThe crucial role of automation in making cell therapies accessible and affordableBuilding successful partnerships to accelerate biotech innovationWhether you're a scientist, investor, or healthcare professional, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore how Deana's vision of "copy-paste" therapy production could transform millions of lives and reshape the biotech landscape!Connect with Deana Mohr:LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4MUVON Therapeutics: https://www.muvon-therapeutics.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a Text Message.Discover how scientists are transforming lives through innovative muscle regeneration therapy. In this captivating episode, Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich, unveils her groundbreaking autologous muscle regeneration technology for treating stress urinary incontinence.Learn how this minimally invasive treatment harnesses the power of a patient's own cells to restore muscle function, offering hope to millions. Diana shares her journey from PhD research to clinical trials, revealing the challenges of translating cutting-edge science into real-world treatments.Listeners will gain insights on:The potential of autologous muscle tissue regeneration and the hurdles of medical innovation.Navigating the complex path from lab to clinicKey differences between muscle-based and CAR-T cell therapiesWhether you're a scientist, investor, or simply curious about medical innovations, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore the forefront of biotech entrepreneurship!Connect with Deana Mohr:LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4MUVON Therapeutics: https://www.muvon-therapeutics.comNext Steps:Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Send us a Text Message.Ever wondered why some biotech facilities thrive while others struggle Alfredo Martínez Mogarra, a Bioprocess Engineer with over 30 years of experience and Chief Operations Manager at VIVEbiotech, reveals the secrets to successful biotech manufacturing.In this eye-opening episode, Alfredo shares critical insights on bridging the gap between lab-scale processes and industrial production.You will get:Strategies for seamless scale-up and risk mitigation in bioprocess developmentTips for fostering crucial interdepartmental collaboration in biotech facilitiesGuidance on leveraging automation and AI for enhanced process control and predictabilityWhether you're a biotech scientist, engineer, or industry professional, this episode is packed with invaluable wisdom to elevate your facility design and operations.Don't miss Alfredo's golden rule: "Think very well before starting doing things." Tune in now and learn how to build a foundation for biotech success!Connect with Alfredo Martínez Mogarra:LinkedIn: https://www.linkedin.com/in/alfredo-martínez-mogarra-a381087Biotech Academy in Rome: https://www.biotechacademy.euNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Send us a Text Message.Ever wondered what it takes to build a large-scale biotech manufacturing facility? Alfredo Martínez Mogarra, a seasoned Bioprocess Engineer with over 30 years of experience and Chief Operations Manager at VIVEbiotech, reveals the secrets behind successful biotech facility design and scale-up. He has been at the forefront of transforming bench processes into industrial realities.In this eye-opening episode, Alfredo shares critical insights on navigating the complex world of biotech manufacturing. Listeners will gain:A deep understanding of the key factors in designing efficient biotech facilitiesStrategies to mitigate risks when scaling up processesTips for fostering successful interdisciplinary collaborationWhether you're a biotech scientist, engineer, or industry professional, this episode is packed with invaluable wisdom to elevate your bioprocessing game.Tune in now and learn how to think holistically about biotech facility design.Connect with Alfredo Martínez Mogarra:LinkedIn: https://www.linkedin.com/in/alfredo-martínez-mogarra-a381087Biotech Academy in Rome: https://www.biotechacademy.euNext Steps:Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessmentDevelop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

In this conversation, Etienne interviews Kathy Keating, a fractional CTO and executive coach. They discuss topics such as finding joy in work, dealing with disagreement and rejection, and the importance of operationalizing processes in growing companies. Kathy emphasizes the need for alignment on the problems worth solving and the value of creating a consistent operational cadence. They also touch on the importance of being a systems thinker and the benefits of writing and documenting ideas and processes. Etienne and Kathy discuss the importance of documentation, decision-making, and operationalizing processes in the role of a CTO. They emphasize the need for clear communication, alignment, and trust within an organization. They also highlight the value of incremental changes and continuous improvement in addressing complex problems. The conversation touches on the relevance of CTO Levels in understanding common challenges faced by CTOs at different levels of experience. Overall, the discussion emphasizes the importance of effective leadership and the role of processes in driving growth and success.Time Stamps00:00 - Introduction and Finding Joy in Work06:27 - Dealing with Disagreement and Rejection09:15 - Operationalizing Processes for Growing Companies13:00 - The Importance of Alignment and Systems Thinking19:10 - The Benefits of Writing and Documenting29:56 - Introduction and the Importance of Documentation35:37 - Operationalizing Processes for Business Growth42:51 - The Value of Incremental Changes and Continuous Improvement50:58 - Understanding Common Challenges with CTO Levels53:20 - Effective Leadership: Communication, Alignment, and Decision-MakingWe have 200+ CTOs in peer groups: Quick Testimonials VideoContact Etienne: Website / YouTube / LinkedIn / X / Instagram / The CTO Podcast WebsiteContact Kathy: Website /LinkedIn Get full access to The CTO Podcast at www.ctopod.com/subscribe